ELA822 / Electra Therap - LARVOL DELTA

Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders… (GlobeNewswire) - "Proceeds from the financing will fund a global pivotal Phase 2/3 study of ELA026 in secondary hemophagocytic lymphohistiocytosis (sHLH), a hyperinflammatory disease with high mortality and a lack of treatment options. The pivotal study is enrolling patients at research sites across the U.S. and Europe and has initiated dosing....Financing will also...advance second pipeline program, ELA822, into the clinic for diseases in immunology and inflammation (I&I)."

Financing • Trial status • Hemophagocytic lymphohistiocytosis